| Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ... New England Journal of Medicine 379 (26), 2495-2505, 2018 | 2397 | 2018 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1663 | 2017 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1594 | 2017 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A Du Bois, J Ledermann, WG McCluggage, ... Annals of Oncology 30 (5), 672-705, 2019 | 1053 | 2019 |
| Basal-like breast carcinomas: clinical outcome and response to chemotherapy S Banerjee, JS Reis-Filho, S Ashley, D Steele, A Ashworth, SR Lakhani, ... Journal of clinical pathology 59 (7), 729-735, 2006 | 424 | 2006 |
| New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential S Banerjee, SB Kaye Clinical cancer research 19 (5), 961-968, 2013 | 420 | 2013 |
| Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ... Nature genetics 49 (5), 680-691, 2017 | 401 | 2017 |
| Exploiting the folate receptor α in oncology M Scaranti, E Cojocaru, S Banerjee, U Banerji Nature reviews clinical oncology 17 (6), 349-359, 2020 | 345 | 2020 |
| Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 309 | 2020 |
| Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer … A Oaknin, AV Tinker, L Gilbert, V Samouëlian, C Mathews, J Brown, ... JAMA oncology 6 (11), 1766-1772, 2020 | 292 | 2020 |
| BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer M Moschetta, A George, SB Kaye, S Banerjee Annals of Oncology 27 (8), 1449-1455, 2016 | 289 | 2016 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double … A Poveda, A Floquet, JA Ledermann, R Asher, RT Penson, AM Oza, ... The Lancet Oncology 22 (5), 620-631, 2021 | 288 | 2021 |
| PARP inhibitors in the management of ovarian cancer: ASCO guideline WP Tew, C Lacchetti, A Ellis, K Maxian, S Banerjee, M Bookman, ... Obstetrical & Gynecological Survey 75 (12), 739-741, 2020 | 251 | 2020 |
| Global cancer control: responding to the growing burden, rising costs and inequalities in access GW Prager, S Braga, B Bystricky, C Qvortrup, C Criscitiello, E Esin, ... ESMO open 3 (2), e000285, 2018 | 243 | 2018 |
| Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo … S Banerjee, KN Moore, N Colombo, G Scambia, BG Kim, A Oaknin, ... The Lancet Oncology 22 (12), 1721-1731, 2021 | 241 | 2021 |
| Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients A George, D Riddell, S Seal, S Talukdar, S Mahamdallie, E Ruark, ... Scientific reports 6 (1), 29506, 2016 | 214 | 2016 |
| Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label … E Pujade-Lauraine, K Fujiwara, JA Ledermann, AM Oza, R Kristeleit, ... The lancet oncology 22 (7), 1034-1046, 2021 | 212 | 2021 |
| Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis … AR Clamp, EC James, IA McNeish, A Dean, JW Kim, DM O'Donnell, ... The Lancet 394 (10214), 2084-2095, 2019 | 180 | 2019 |
| Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial P DiSilvestro, S Banerjee, N Colombo, G Scambia, BG Kim, A Oaknin, ... Obstetrical & Gynecological Survey 78 (1), 25-27, 2023 | 176 | 2023 |
| Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer A George, S Kaye, S Banerjee Nature reviews Clinical oncology 14 (5), 284-296, 2017 | 174 | 2017 |
